INTRODUCTION: Despite advances in therapy for multiple myeloma, patients have continued to experience relapse. We sought to better understand this. OBJECTIVE: To identify factors that predict early relapse in patients with multiple myeloma who receive autologous hematopoietic peripheral stem cell transplant (HSCT). METHODS: Retrospective analysis of Kaiser Permanente Southern California patients who received HSCTs between 2008 and 2012. RESULTS: A total of 141 patients were included. Factors found to be associated with inferior progression-free survival were disease status less than complete response at the time of HSCT, no use of maintenance therapy after HSCT, International Staging System stage III, and high Freiburg Comorbidity Index. Disease status less than complete response, stage III, higher Freiburg Comorbidity Index, no use of maintenance therapy, and male sex were the most predictive factors for early relapse (< 18 months). DISCUSSION: Our results identified a subgroup of high-risk individuals with multiple myeloma who will continue to do poorly after HSCT with the best available treatment using a combination of proteasome inhibitors and immunomodulatory drugs. These results highlight the need for consideration of alternative therapy in such instances.
INTRODUCTION: Despite advances in therapy for multiple myeloma, patients have continued to experience relapse. We sought to better understand this. OBJECTIVE: To identify factors that predict early relapse in patients with multiple myeloma who receive autologous hematopoietic peripheral stem cell transplant (HSCT). METHODS: Retrospective analysis of Kaiser Permanente Southern Californiapatients who received HSCTs between 2008 and 2012. RESULTS: A total of 141 patients were included. Factors found to be associated with inferior progression-free survival were disease status less than complete response at the time of HSCT, no use of maintenance therapy after HSCT, International Staging System stage III, and high Freiburg Comorbidity Index. Disease status less than complete response, stage III, higher Freiburg Comorbidity Index, no use of maintenance therapy, and male sex were the most predictive factors for early relapse (< 18 months). DISCUSSION: Our results identified a subgroup of high-risk individuals with multiple myeloma who will continue to do poorly after HSCT with the best available treatment using a combination of proteasome inhibitors and immunomodulatory drugs. These results highlight the need for consideration of alternative therapy in such instances.
Authors: Morie A Gertz; Shaji Kumar; Martha Q Lacy; Angela Dispenzieri; David Dingli; Suzanne R Hayman; Francis K Buadi; William J Hogan Journal: Blood Date: 2010-01-20 Impact factor: 22.113
Authors: Thomas Martin; Rachid Baz; Don M Benson; Nikoletta Lendvai; Jeffrey Wolf; Pamela Munster; Alexander M Lesokhin; Claudine Wack; Eric Charpentier; Frank Campana; Ravi Vij Journal: Blood Date: 2017-05-08 Impact factor: 22.113
Authors: W J Chng; M A Gertz; T-H Chung; S Van Wier; J J Keats; A Baker; P L Bergsagel; J Carpten; R Fonseca Journal: Leukemia Date: 2010-03-11 Impact factor: 11.528
Authors: Jesús F San-Miguel; Vânia T M Hungria; Sung-Soo Yoon; Meral Beksac; Meletios Athanasios Dimopoulos; Ashraf Elghandour; Wieslaw Wiktor Jedrzejczak; Andreas Günther; Thanyaphong Na Nakorn; Noppadol Siritanaratkul; Paolo Corradini; Suporn Chuncharunee; Je-Jung Lee; Robert L Schlossman; Tatiana Shelekhova; Kwee Yong; Daryl Tan; Tontanai Numbenjapon; Jamie D Cavenagh; Jian Hou; Richard LeBlanc; Hareth Nahi; Lugui Qiu; Hans Salwender; Stefano Pulini; Philippe Moreau; Krzysztof Warzocha; Darrell White; Joan Bladé; WenMing Chen; Javier de la Rubia; Peter Gimsing; Sagar Lonial; Jonathan L Kaufman; Enrique M Ocio; Ljupco Veskovski; Sang Kyun Sohn; Ming-Chung Wang; Jae Hoon Lee; Hermann Einsele; Monika Sopala; Claudia Corrado; Bourras-Rezki Bengoudifa; Florence Binlich; Paul G Richardson Journal: Lancet Oncol Date: 2014-09-18 Impact factor: 41.316
Authors: N Majithia; S V Rajkumar; M Q Lacy; F K Buadi; A Dispenzieri; M A Gertz; S R Hayman; D Dingli; P Kapoor; L Hwa; J A Lust; S J Russell; R S Go; R A Kyle; S K Kumar Journal: Leukemia Date: 2016-05-23 Impact factor: 11.528
Authors: S K Kumar; A Dispenzieri; R Fraser; F Mingwei; G Akpek; R Cornell; M Kharfan-Dabaja; C Freytes; S Hashmi; G Hildebrandt; L Holmberg; R Kyle; H Lazarus; C Lee; J Mikhael; T Nishihori; J Tay; S Usmani; D Vesole; R Vij; B Wirk; A Krishnan; C Gasparetto; T Mark; Y Nieto; P Hari; A D'Souza Journal: Leukemia Date: 2017-11-16 Impact factor: 11.528